Monday , July 23 2018
Home / Resources / Articles / Bezafibrate Can Prevent or Delay Type 2 Diabetes

Bezafibrate Can Prevent or Delay Type 2 Diabetes

Apr 28, 2009

Bezafibrate, a pan-PPAR agonist used widely for treating dyslipidemia in the UK, appears to prevent or delay the development of Type 2 diabetes, according to results of a retrospective study.

“If prospective trials bear out these retrospective findings, bezafibrate could become an oral antidiabetic that also reduces cardiovascular risk,” Dr. James H. Flory told Reuters Health.

Dr. Flory, from the University of Pennsylvania School of Medicine, Philadelphia, and colleagues used observational data from the UK’s General Practice Research Database to examine their a priori hypothesis that bezafibrate is unique among fibrates in reducing diabetes risk. The cohort included 12,161 patients on bezafibrate and 4,191 who took other fibrates.
The incidence of Type 2 diabetes among bezafibrate users was 8.5 cases per 1,000 patient-years, the authors report, compared with 14.4 cases per 1,000 patient years among users of other fibrates.

In a fully adjusted model, the hazard ratio for incident Type 2 diabetes was 0.66 for bezafibrate users compared with users of other fibrates.

Moreover, the investigators note, the risk of developing diabetes decreased monotonically as the duration of bezafibrate therapy increased.

Among patients with preexisting diabetes, bezafibrate use was associated with a significantly lower risk of progression to antidiabetic medication use and with a trend toward a lower risk of progression to insulin therapy, compared with use of other fibrates.

“I do think that at least one prospective randomized controlled trial is needed before bezafibrate can be indicated to prevent or treat diabetes,” Dr. Flory said. “This is especially true in the United States, where bezafibrate is not even on the market.”
He added, “Right now it is not clear that any of the available diabetes medications are safe from a cardiovascular standpoint. And bezafibrate would be cheap because it is off patent, but because it is off patent industry is not likely to take care of this research for us.”

Diabetes Care April 2009;32:547-551.



When Doctors Prescribe Exercise, Patients Get Moving: Exercise prescriptions get inactive adults moving, a new study shows. The study, published in this week’s Archives of Internal Medicine, is a “milestone” because it proves that exercise prescriptions work. It’s “quite rare” for U.S. doctors to prescribe exercise, but that’s changing. In a new study, researchers trained family physicians in how to deliver custom-made exercise prescriptions for inactive adults during a 15-minute doctor visit. Those doctors gave more than 2,200 inactive adults exercise prescriptions that were tailored for each patient. For comparison, they didn’t give exercise prescriptions to nearly 2,070 other sedentary adults.  Six months later, the patients who had gotten the exercise prescriptions reported more physical activity than those who hadn’t received exercise prescriptions. The effects were “clinically relevant.” “Advice alone does not do it… It must be a customized and personalized prescription in order to get the best benefit.” McDermott says exercise needs to be prescribed as thoroughly as a pill.